NEO 100 Enables Noninvasive, Therapeutically Effective Delivery of Pharmaceutical Agents

Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models

Authors: Weijun Wang, MD¹, Steve Swenson, PhD¹, Hee-Yeon Cho, PhD¹, Florence M. Hofman, PhD², Axel H. Schönthal, PhD³, and Thomas C. Chen, MD, PhD^1,2

This study demonstrates that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutically effective brain delivery of a pharmaceutical agent that otherwise does not efficiently cross the BBB.

¹ Departments of Neurosurgery, ² Department of Pathology, ³ Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California